ABO1020 / Suzhou Abogen Biosci - LARVOL DELTA

Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial. (PubMed, Med) - P2/3 | "ABO1020 was well tolerated and conferred 66.18% protection against symptomatic COVID-19 in adults."

Clinical • Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Pain

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - P2/3 | N=14168 | Active, not recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Trial primary completion date: Jul 2023 ➔ Apr 2023

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - P2/3 | N=15030 | Active, not recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - P2/3 | N=15030 | Recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Active, not recruiting ➔ Recruiting | Phase classification: P1/2 ➔ P2/3 | N=30 ➔ 15030 | Trial completion date: Nov 2023 ➔ Jul 2024 | Trial primary completion date: Dec 2022 ➔ Jul 2023

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd.

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases